ARTA
GNMX

A.R.T. Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

A.R.T. Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,949
Closed -$13K – 1839
2018
Q3 		$13K Sell
10,949
-2,645
-19% -$2.96K ﹤0.01% 1358
2018
Q2 		$15K Buy
+13,594
New +$20.7K ﹤0.01% 1368
2018
Q1 		– Sell
-41,879
Closed -$50K – 1895
2017
Q4 		$50K Sell
41,879
-32,764
-44% -$44.7K ﹤0.01% 1297
2017
Q3 		$94K Sell
74,643
-42,621
-36% -$54.5K ﹤0.01% 1216
2017
Q2 		$155K Buy
117,264
+69,595
+146% +$101K 0.01% 1205
2017
Q1 		$88K Buy
+47,669
New +$216K ﹤0.01% 1282

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

A.R.T. Advisors's GNMX Position: Q4 2018 in Review

A.R.T. Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2018, closing a stake of 10,949 shares — an estimated $13K sold.

A.R.T. Advisors first reported a position in GNMX in Q1 2017 and held it in 6 quarters. The position peaked at $155K in Q2 2017. 38 funds tracked by Wall St. Rank hold GNMX as of Q4 2018.

  • A.R.T. Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q4 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 10,949 Aevi Genomic Medicine Inc shares in Q4 2018, an estimated $13K.
  • A.R.T. Advisors first reported a position in Aevi Genomic Medicine Inc in Q1 2017 and held it in 6 quarters.
  • A.R.T. Advisors's Aevi Genomic Medicine Inc position peaked at $155K in Q2 2017.
  • 38 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.